7,135 Shares in Novo Nordisk A/S $NVO Bought by SCS Capital Management LLC

Key Points

• SCS Capital Management LLC purchased 7,135 shares of Novo Nordisk A/S for about $503,000 during the first quarter as indicated in a recent SEC filing.
• The company reported earnings of $0.97 per share, exceeding analyst expectations of $0.93, and showed a net margin of 35.60% for the quarter ending August 6th.
• Novo Nordisk A/S has also seen a variety of changes in ratings from analysts, with the average rating now at "Hold" and an average price target of $81.00.

SCS Capital Management LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 7,135 shares of the company's stock, valued at approximately $503,000.

Other large investors have also recently made changes to their positions in the company. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $29,000. North Capital Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at $27,000. Copeland Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after buying an additional 255 shares in the last quarter. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S in the first quarter valued at $30,000. Finally, Mascagni Wealth Management Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $40,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 0.1%

NVO opened at $54.29 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company's 50-day moving average is $58.25 and its 200 day moving average is $66.74. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $138.22. The firm has a market capitalization of $242.40 billion, a P/E ratio of 14.91, a PEG ratio of 2.06 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

Analysts Set New Price Targets

A number of research firms have weighed in on NVO. Dbs Bank raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, August 22nd. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Zacks Research lowered shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research report on Wednesday, August 20th. BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. Finally, HSBC lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target on the stock. in a research report on Thursday, July 31st. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $81.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.